Terapia Ranbaxy receives 3-year GMP certification renewal for Bucharest facility

The Terapia Ranbaxy production facility based in Bucharest (Romania) has received a three-year certification renewal for adherence to GMP standards at the operational level by the National Agency of Medicine.

Last June, Ranbaxy had announced the completion of the acquisition formalities by Ranbaxy Netherlands BV of 96.7 per cent of the top Romanian generics company Terapia SA. Ranbaxy says the combined operations of Terapia Ranbaxy has become the largest Romanian generics company. The Bucharest site became a part of Terapia Ranbaxy in August 2005, when Terapia acquired the Promedic and Pharmaplant facilities.

"At the Bucharest site, we manufacture over 60 products comprising liquids (drops, syrups and ophthalmic solutions) and solids," said Dragos Damian, CEO Terapia Ranbaxy. "We have more than 100 highly qualified specialists working at this site who have worked to very high standards an have cooperated extremely well with the Quality Assurance Department to get this important certification," Damian added.

Last month, the company had received the manufacturing and import authorisation and was also granted permission for batch testing and release activities for products manufactured outside the European Union, following inspections in February by the Romanian regulatory agency.

In November last year, Terapia Ranbaxy announced the completion of its investment in a new logistic center in Otopeni Bucharest aimed at increasing its warehousing facilities for Ranbaxy products imported from India.

Established in 1921, Terapia has a strong brand name and a consistent track record of growth and profitability.